key: cord-1048086-p5prlrf2 authors: Ehsani, Amir Hooshang; Nasimi, Maryam; Bigdelo, Zeinab title: Pityriasis rosea as a cutaneous manifestation of COVID‐19 infection date: 2020-05-02 journal: J Eur Acad Dermatol Venereol DOI: 10.1111/jdv.16579 sha: ce0ce06ff2f1853d916e34dcb0b31ef5f770225a doc_id: 1048086 cord_uid: p5prlrf2 Cutaneous manifestation has been reported in 0.2% of patients infected by COVID‐19 in China, and 18 out of 88 patients from Italy. The most commonly reported features are exanthomatous rash, urticaria, chickenpox like vesicles, petechiae, and acute hemorrhagic edema of infancy. Herein, we report one case of pityriasis rosea in a patient infected with COVID‐19. Dr. Bigdelo has nothing to disclose. Dr. Ehsani has nothing to disclose. Dr. Nasimi has nothing to disclose. Dear editor, Cutaneous manifestation has been reported in 0.2% of patients infected by COVID-19 in China [1] , and 18 out of 88 patients from Italy [2] . The most commonly reported features are exanthomatous rash, urticaria, chickenpox like vesicles, petechiae, and acute hemorrhagic edema of infancy [3] [4] [5] . Herein, we report one case of pityriasis rosea in a patient infected with COVID-19. A 27 years old man with no previous medical history, presented initially with low grade fever, fatigue, gastroenteritis and anorexia. Three days later, an erythematous and scaly annular plaque appeared on the left forearm, and several days later generalized papular and plaque type lesions occurred all over the trunk and upper extremities in a shape that resembles drooping pine-tree branches ( Figure 1 ). Lesions continued to disseminate for 5 days and became pruritic. A chest CT showed patchy ground glass infiltration at the peripheral and base of the both lungs consistent with the COVID-19 infection. Laboratory investigation revealed no specific abnormality and blood oxygen saturation was normal. Patient had history of long term intake of sertraline and propranolol without any change in the treatment regime during last months. Family history of patient uncovered confirmed COVID-19 infection in mother 50 days and father 40 days earlier with fever, dyspnea, myalgia, and ground glass features in the chest CT. As patient general condition and oxygen saturation was normal, patient was followed up out-patiently with topical corticosteroid and anti-histamine (cetirizine) for pruritic lesions and acetaminophen for fever, if indicated. This article is protected by copyright. All rights reserved The described case here seems reminiscent of pityriasis rosea with typical presentation of herald patch with collaret of trailing scale that followed with smaller disseminated lesion developing along the lines of cleavage. Pityriasis rosea has been usually associated with reactivation of herpesvirus 6 and 7, but other viral etiology, vaccination, and drugs have also been implicated as the cause of this reaction [6] . Our case could be a cutaneous manifestation of COVID-19 viral infection, and help dermatologist to get familiar with skin rash due to this new viral infection. Clinical characteristics of coronavirus disease 19 in China Cutaneous manifestations in COVID-19: a first perspective Cutaneous manifestations in COVID-19: a new contribution A distinctive skin rash associated with Coronavirus Disease Viral exanthem in COVID-19, a clinical enigma with biological significance Harper's Textbook of Pediatric Dermatology The patient in this manuscript has given written informed consent to the publication of his case details.